Efficacy and safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors

Kazuyuki Matsumoto; Hironari Kato; Koichiro Tsutsumi; Sho Mizukawa; Syuntaro Yabe; Hiroyuki Seki; Yutaka Akimoto; Daisuke Uchida; Takeshi Tomoda; Naoki Yamamoto; Shigeru Horiguchi; Hiroyuki Okada

Efficacy and safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors

Kazuyuki Matsumoto, Hironari Kato, Koichiro Tsutsumi, Sho Mizukawa, Syuntaro Yabe, Hiroyuki Seki, Yutaka Akimoto, Daisuke Uchida, Takeshi Tomoda, Naoki Yamamoto, Shigeru Horiguchi, Hiroyuki Okada

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Recently, endoscopic ultrasonography (EUS)-guided ethanol ablation for small pancreatic neuroendocrine tumors (p-NETs) has been reported. However, the efficacy and safety of the technique remain unclear. We have launched a prospective pilot study of EUS-guided ethanol ablation for p-NETs. The major eligibility criteria are the presence of a pathologically diagnosed grade (G) 1 or G2 p-NET, a tumor size of ≤2cm, and being a poor candidate for surgery. A total of 5 patients will be treated. The primary endpoint will be the complete ablation rate at 1 month after treatment.

Original language	English
Pages (from-to)	313-316
Number of pages	4
Journal	Acta medica Okayama
Volume	70
Issue number	4
Publication status	Published - 2016

Keywords

EUS-guided
Ethanol ablation
Pancreatic neuroendocrine tumor

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{fe7d26230cdc4dac9cdc4778b1a7e28b,

title = "Efficacy and safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors",

abstract = "Recently, endoscopic ultrasonography (EUS)-guided ethanol ablation for small pancreatic neuroendocrine tumors (p-NETs) has been reported. However, the efficacy and safety of the technique remain unclear. We have launched a prospective pilot study of EUS-guided ethanol ablation for p-NETs. The major eligibility criteria are the presence of a pathologically diagnosed grade (G) 1 or G2 p-NET, a tumor size of ≤2cm, and being a poor candidate for surgery. A total of 5 patients will be treated. The primary endpoint will be the complete ablation rate at 1 month after treatment.",

keywords = "EUS-guided, Ethanol ablation, Pancreatic neuroendocrine tumor",

author = "Kazuyuki Matsumoto and Hironari Kato and Koichiro Tsutsumi and Sho Mizukawa and Syuntaro Yabe and Hiroyuki Seki and Yutaka Akimoto and Daisuke Uchida and Takeshi Tomoda and Naoki Yamamoto and Shigeru Horiguchi and Hiroyuki Okada",

note = "Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",

year = "2016",

language = "English",

volume = "70",

pages = "313--316",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "4",

}

TY - JOUR

T1 - Efficacy and safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors

AU - Matsumoto, Kazuyuki

AU - Kato, Hironari

AU - Tsutsumi, Koichiro

AU - Mizukawa, Sho

AU - Yabe, Syuntaro

AU - Seki, Hiroyuki

AU - Akimoto, Yutaka

AU - Uchida, Daisuke

AU - Tomoda, Takeshi

AU - Yamamoto, Naoki

AU - Horiguchi, Shigeru

AU - Okada, Hiroyuki

PY - 2016

Y1 - 2016

N2 - Recently, endoscopic ultrasonography (EUS)-guided ethanol ablation for small pancreatic neuroendocrine tumors (p-NETs) has been reported. However, the efficacy and safety of the technique remain unclear. We have launched a prospective pilot study of EUS-guided ethanol ablation for p-NETs. The major eligibility criteria are the presence of a pathologically diagnosed grade (G) 1 or G2 p-NET, a tumor size of ≤2cm, and being a poor candidate for surgery. A total of 5 patients will be treated. The primary endpoint will be the complete ablation rate at 1 month after treatment.

AB - Recently, endoscopic ultrasonography (EUS)-guided ethanol ablation for small pancreatic neuroendocrine tumors (p-NETs) has been reported. However, the efficacy and safety of the technique remain unclear. We have launched a prospective pilot study of EUS-guided ethanol ablation for p-NETs. The major eligibility criteria are the presence of a pathologically diagnosed grade (G) 1 or G2 p-NET, a tumor size of ≤2cm, and being a poor candidate for surgery. A total of 5 patients will be treated. The primary endpoint will be the complete ablation rate at 1 month after treatment.

KW - EUS-guided

KW - Ethanol ablation

KW - Pancreatic neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=84984856630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984856630&partnerID=8YFLogxK

M3 - Article

C2 - 27549680

AN - SCOPUS:84984856630

SN - 0386-300X

VL - 70

SP - 313

EP - 316

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 4

ER -

Efficacy and safety of endoscopic ultrasound-guided ethanol ablation therapy for pancreatic neuroendocrine tumors

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this